Noll G, Wenzel R R, Shaw S, Lüscher T F
University Hospital Zürich, Cardiovascular Research, Switzerland.
J Hypertens Suppl. 1998 Jan;16(1):S17-24.
The sympathetic nervous system is an important cardiovascular regulator, particularly during stress and exercise; its sympathetic nervous activity is regulated in centers in the brain stem and transmitted to organs and blood vessels that are innervated by sympathetic nerve endings. In the heart, the sympathetic nervous system increases heart rate and contractility. The effect of the sympathetic nervous system in different vascular beds depends on the degree of innervation, the distribution of postjunctional receptors and the effect of local mediators. Overactivation of the sympathetic nervous system may lead to hypertension and is involved in heart failure. The degree of sympathetic activation determines prognosis in heart failure. Hence, vasodilators ideally should also blunt sympathetic activity, or at least avoid activating it. DIFFERENCES AMONG CALCIUM ANTAGONISTS: Calcium antagonists are widely used for the treatment of hypertension and coronary artery disease. Their main mechanism of action is inhibition of L-type Ca2+ channels. Short-acting nifedipine leads to a marked increase in heart rate, sympathetic nerve activity and plasma catecholamines, similar to those induced by a cold pressor test. With long-acting nifedipine heart rate does not increase, but sympathetic nerve activity does increase. Other calcium antagonists have been less thoroughly investigated, but indirect evidence suggests differences between the different classes. Verapamil and diltiazem lower heart rate. Plasma noradrenalin measurements suggest that verapamil does not stimulate the sympathetic nervous system, but tends to suppress it. Second-generation dihydropyridines with longer duration of action do not increase heart rate; their effects on peripheral sympathetic nerve activity are not clear. Thus, in summary, the different classes of calcium antagonists differ with regard to their effects on sympathetic nerve activation. A decrease in heart rate and nerve activity might be beneficial for long-term prognosis, particularly in hypertension and heart failure.
交感神经系统是重要的心血管调节系统,在应激和运动期间尤为如此;其交感神经活动在脑干的中枢进行调节,并传递至由交感神经末梢支配的器官和血管。在心脏,交感神经系统可增加心率和心肌收缩力。交感神经系统在不同血管床的作用取决于神经支配程度、节后受体的分布以及局部介质的作用。交感神经系统过度激活可能导致高血压,并与心力衰竭有关。交感神经激活程度决定心力衰竭的预后。因此,理想的血管扩张剂也应抑制交感神经活动,或至少避免激活交感神经活动。钙拮抗剂之间的差异:钙拮抗剂广泛用于治疗高血压和冠状动脉疾病。其主要作用机制是抑制L型Ca2+通道。短效硝苯地平可导致心率、交感神经活动和血浆儿茶酚胺显著增加,类似于冷加压试验所诱发的变化。长效硝苯地平不会使心率增加,但交感神经活动会增加。其他钙拮抗剂的研究尚不充分,但间接证据表明不同类别之间存在差异。维拉帕米和地尔硫䓬可降低心率。血浆去甲肾上腺素测量结果表明,维拉帕米不会刺激交感神经系统,反而倾向于抑制交感神经系统。作用持续时间更长的第二代二氢吡啶类药物不会增加心率;它们对外周交感神经活动的影响尚不清楚。因此,综上所述,不同类别的钙拮抗剂在对交感神经激活的影响方面存在差异。心率和神经活动降低可能对长期预后有益,尤其是在高血压和心力衰竭患者中。